STUDY RESULTS OF SAFETY (TOLER ANCE) OF THE DRUG "RECOMBINANT INTERFERON-LAMBDA"
In recent years, there has been a decrease in the efficacy of etiotropic agents in the treatment of mastitis in cows, associated with the development of antibiotic resistance in microorganisms. One of the promising areas of clinical pharmacology is the use of drugs based on interferons (IFNs), which, in addition to antiviral, immunocorrective and antimicrobial effects, are involved in maintaining the homeostasis of the animal body. Interferon - λ was discovered relatively recently, its protective role on the mucous membranes of the respiratory and digestive systems, urinary organs, etc. has been proven. However, unlike type I and II interferons, IFN - λ drugs are practically not used in veterinary medicine. The article presents the results of studying the safety (tolerance) of the new drug «Recombinant interferon lambda» in order to assess the prospects for its further use in clinical practice, in particular, in the treatment of mastitis in cows. As a result of the studies, it was found that intramuscular administration of recombinant interferon - λ to lactating cows at a therapeutic and threefold therapeutic doses does not adversely affect the general clinical condition of the animals, the main metabolic indicators and the blood morphological composition.